{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061123","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.148312+00:00","generated_at":"2026-06-08T11:05:00.131004+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tenaya Q3 net loss $29.1M; first patient dosed in TN-201 HCM trial","bullets":["Q3 net loss $29.1M ($0.39/share); R&D $23.1M, G&A $7.8M; cash $128.1M into H1 2025.","First patient dosed in MyPeak-1 Phase 1b trial of TN-201 for MYBPC3-associated HCM.","FDA cleared TN-401 IND for PKP2-ARVC and granted Fast Track designation in Nov 2023.","Positive Phase 1 data for TN-301 (HDAC6 inhibitor) in HFpEF presented at HFSA 2023.","EMA granted Orphan Medicinal Product designation for TN-401 in Sep 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061123","json":"https://secwatch.observer/filing/0000950170-23-061123.json","markdown":"https://secwatch.observer/filing/0000950170-23-061123.md","text":"https://secwatch.observer/filing/0000950170-23-061123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023061123/0000950170-23-061123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023061123/tnya-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T11:05:00.131004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"47d24a45f45ba27603d737c83549ef0b93963272","claim":"Tenaya Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $29.1 million, or $0.39 per share, EPS $0.39 per share.","evidence_excerpt":"Net loss for the quarter ended September 30, 2023, was $29.1 million, or $0.39 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023061123/0000950170-23-061123-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"$29.1 million, or $0.39 per share"},{"label":"EPS","value":"$0.39 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}